Phosphorex Presents Its Nanosuspension Formulation at CRS Meeting
Hopkinton, MA , July 27, 2021 – Dr. Bin Wu, Phosphorex’ President and CEO, today presented “A Novel Indirubin Nanosuspension for Potential Treatment of Glioblastoma” at the 2021 Controlled Release Society (CRS) Virtual Annual Meeting. He demonstrated how nanotechnology can be an ideal solution for complex issues such as solubility and deliverability of anti-tumor agents. The data in his presentation showed nanosuspension of indirubin, a natural GSK-3 inhibitor, enabled parental delivery and suppressed tumor growth in an animal glioblastoma model.
A Novel Indirubin Nanosuspension for Potential Treatment of Glioblastoma